Filana Therapeutics, Inc.
FLNAHealthcare|Biotechnology|US
$0.45
+0.00 (+0.38%)
DCF Value
$1.85
Tangible Book / Share
$1.20
Cash / Share
$0.97
About
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
Stock Price
-77.9%(1Y)
1M
-44.4%
3M
-54.5%
6M
-65.2%
YTD
-77.9%
1Y
-77.9%
3Y
-77.9%
5Y
-77.9%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$21.9M
Employees17 (-43% YoY)
CEORichard Jon Barry
IPO DateJul 14, 2000
Beta-0.66
52-Week Range$0.4252 – $3.45
Avg Volume1,556,840
ExchangeNASDAQ
Websitefilanatx.com
Ownership
Float97.1%
Shares Outstanding48.3M
Recent Insider Trades
Barry RichardBUY
Sep 30, 2026100,000 shares @ $0.92
Barry RichardBUY
Sep 29, 2026206,813 shares @ $0.90
Barry RichardBUY
Sep 28, 202693,091 shares @ $0.84
Recent News
Filana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient Cells
Oct 28, 2026 · globenewswire.com
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
Oct 9, 2026 · globenewswire.com
Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward
Sep 22, 2026 · benzinga.com
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
Sep 22, 2026 · globenewswire.com
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Aug 12, 2026 · gurufocus.com
Data last updated: Nov 9, 2026, 04:11 AM